SEARCH:   Advanced

Blood, 15 August 2005, Vol. 106, No. 4, pp. 1419-1422. Prepublished online as a Blood First Edition Paper on May 3, 2005; DOI 10.1182/blood-2005-03-0899. This Article Full Text (PDF) All Versions of this Article: 2005-03-0899v1 106/4/1419    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Cazzaniga, G. Articles by Falini, B. Search for Related Content PubMed PubMed Citation Articles by Cazzaniga, G. Articles by Falini, B. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 4, 2005 Accepted April 24, 2005 Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype Giovanni Cazzaniga, Maria G Dell'Oro, Cristina Mecucci, Emanuela Giarin, Riccardo Masetti, Vincenzo Rossi, Franco Locatelli, Massimo F Martelli, Giuseppe Basso, Andrea Pession, Andrea Biondi*, and Brunangelo Falini Pediatric Clinic, M.Tettamanti Research Center, San Gerardo Hospital, University of Milan-Bicocca, Monza, Italy Institute of Hematology, University of Perugia, Perugia, Italy Pediatric Clinic, Onco-Hematology, University of Padua, Padova, Italy Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy Paediatric Haematology and Oncology, IRCCS Policlinico San Matteo, Pavia, Italy * Corresponding author; email: andrea.biondi{at}unimib.it. Nucleophosmin (NPM) is a nucleo-cytoplasmic shuttling protein involved in leukemia-associated chromosomal translocations, which regulates the ARF-p53 tumor-suppressor pathway. Recently, it has been demonstrated that mutations of the NPM1 gene alter the protein at its C-terminal, causing its cytoplasmic localization. Cytoplasmic NPM was detected in 35% of adult patients with primary non-M3 acute myeloid leukemia (AML), mainly associated with normal karyotype. We evaluated the prevalence of NPM1 gene mutation in non-M3 childhood AML patients enrolled in the ongoing AIEOP AML02 protocol in Italy. NPM1 mutations were found in 7/107 (6.5%) successfully analyzed patients. NPM1 mutated patients carried a normal karyotype (7/26, 27.1%) and were older in age. Thus, NPM1 mutation is a frequent abnormality in AML patients without known genetic marker, it may represents a new target to monitor minimal residual disease in AML, and a potential candidate for alternative and targeted treatments. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: I. H. I. M. Hollink, M. M. van den Heuvel-Eibrink, M. Zimmermann, B. V. Balgobind, S. T. C. J. M. Arentsen-Peters, M. Alders, A. Willasch, G. J. L. Kaspers, J. Trka, A. Baruchel, et al. Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia Blood, June 4, 2009; 113(23): 5951 - 5960. [Abstract] [Full Text] [PDF] S. P. Cullen, I. S. Afonina, R. Donadini, A. U. Luthi, J. P. Medema, P. I. Bird, and S. J. Martin Nucleophosmin Is Cleaved and Inactivated by the Cytotoxic Granule Protease Granzyme M during Natural Killer Cell-mediated Killing J. Biol. Chem., February 20, 2009; 284(8): 5137 - 5147. [Abstract] [Full Text] [PDF] E. Morra, G. Barosi, A. Bosi, F. Ferrara, F. Locatelli, M. Marchetti, G. Martinelli, C. Mecucci, M. Vignetti, and S. Tura Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation Haematologica, January 1, 2009; 94(1): 102 - 112. [Abstract] [Full Text] [PDF] C. Boonthimat, W. Thongnoppakhun, and C. U. Auewarakul Nucleophosmin mutation in Southeast Asian acute myeloid leukemia: eight novel variants, FLT3 coexistence and prognostic impact of NPM1/FLT3 mutations Haematologica, October 1, 2008; 93(10): 1565 - 1569. [Abstract] [Full Text] [PDF] A. Liso, F. Castiglione, A. Cappuccio, F. Stracci, R. F. Schlenk, S. Amadori, C. Thiede, S. Schnittger, P. J.M. Valk, K. Dohner, et al. A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1) Haematologica, August 1, 2008; 93(8): 1219 - 1226. [Abstract] [Full Text] [PDF] T. S. Laughlin, M. W. Becker, J. L. Liesveld, D. A. Mulford, C. N. Abboud, P. Brown, and P. G. Rothberg Rapid Method for Detection of Mutations in the Nucleophosmin Gene in Acute Myeloid Leukemia J. Mol. Diagn., July 1, 2008; 10(4): 338 - 345. [Abstract] [Full Text] [PDF] B. Lowenberg Acute Myeloid Leukemia: The Challenge of Capturing Disease Variety Hematology, January 1, 2008; 2008(1): 1 - 11. [Abstract] [Full Text] [PDF] G. J.L. Kaspers and C. M. Zwaan Pediatric acute myeloid leukemia: towards high-quality cure of all patients Haematologica, November 1, 2007; 92(11): 1519 - 1532. [Abstract] [Full Text] [PDF] D. C. Link, G. Kunter, Y. Kasai, Y. Zhao, T. Miner, M. D. McLellan, R. E. Ries, D. Kapur, R. Nagarajan, D. C. Dale, et al. Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia Blood, September 1, 2007; 110(5): 1648 - 1655. [Abstract] [Full Text] [PDF] P. Brown, E. McIntyre, R. Rau, S. Meshinchi, N. Lacayo, G. Dahl, T. A. Alonzo, M. Chang, R. J. Arceci, and D. Small The incidence and clinical significance of nucleophosmin mutations in childhood AML Blood, August 1, 2007; 110(3): 979 - 985. [Abstract] [Full Text] [PDF] N. Bolli, I. Nicoletti, M. F. De Marco, B. Bigerna, A. Pucciarini, R. Mannucci, M. P. Martelli, A. Liso, C. Mecucci, F. Fabbiano, et al. Born to Be Exported: COOH-Terminal Nuclear Export Signals of Different Strength Ensure Cytoplasmic Accumulation of Nucleophosmin Leukemic Mutants Cancer Res., July 1, 2007; 67(13): 6230 - 6237. [Abstract] [Full Text] [PDF] B. Falini, I. Nicoletti, N. Bolli, M. P. Martelli, A. Liso, P. Gorello, F. Mandelli, C. Mecucci, and M. F. Martelli Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias Haematologica, April 1, 2007; 92(4): 519 - 532. [Abstract] [Full Text] [PDF] S. Meshinchi and R. J. Arceci Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia Oncologist, March 1, 2007; 12(3): 341 - 355. [Abstract] [Full Text] [PDF] B. Falini, I. Nicoletti, M. F. Martelli, and C. Mecucci Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features Blood, February 1, 2007; 109(3): 874 - 885. [Abstract] [Full Text] [PDF] H. Dohner Implication of the Molecular Characterization of Acute Myeloid Leukemia Hematology, January 1, 2007; 2007(1): 412 - 419. [Abstract] [Full Text] [PDF] B. Falini, M. P. Martelli, N. Bolli, R. Bonasso, E. Ghia, M. T. Pallotta, D. Diverio, I. Nicoletti, R. Pacini, A. Tabarrini, et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia Blood, September 15, 2006; 108(6): 1999 - 2005. [Abstract] [Full Text] [PDF] B. Falini, N. Bolli, J. Shan, M. P. Martelli, A. Liso, A. Pucciarini, B. Bigerna, L. Pasqualucci, R. Mannucci, R. Rosati, et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML Blood, June 1, 2006; 107(11): 4514 - 4523. [Abstract] [Full Text] [PDF] C. Thiede, S. Koch, E. Creutzig, C. Steudel, T. Illmer, M. Schaich, G. Ehninger, and for the Deutsche Studieninitiative Leukamie (DSIL) Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML) Blood, May 15, 2006; 107(10): 4011 - 4020. [Abstract] [Full Text] [PDF] G. Roti, R. Rosati, R. Bonasso, P. Gorello, D. Diverio, M. F. Martelli, B. Falini, C. Mecucci, and for the Gruppo Italiano Malattie Ematologiche dell Denaturing High-Performance Liquid Chromatography: A Valid Approach for Identifying NPM1 Mutations in Acute Myeloid Leukemia J. Mol. Diagn., May 1, 2006; 8(2): 254 - 259. [Abstract] [Full Text] [PDF] W.-C. Chou, J.-L. Tang, L.-I. Lin, M. Yao, W. Tsay, C.-Y. Chen, S.-J. Wu, C.-F. Huang, R.-J. Chiou, M.-H. Tseng, et al. Nucleophosmin Mutations in De novo Acute Myeloid Leukemia: The Age-Dependent Incidences and the Stability during Disease Evolution. Cancer Res., March 15, 2006; 66(6): 3310 - 3316. [Abstract] [Full Text] [PDF] S. Schnittger, C. Schoch, W. Kern, C. Mecucci, C. Tschulik, M. F. Martelli, T. Haferlach, W. Hiddemann, and B. Falini Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype Blood, December 1, 2005; 106(12): 3733 - 3739. [Abstract] [Full Text] [PDF] K. Dohner, R. F. Schlenk, M. Habdank, C. Scholl, F. G. Rucker, A. Corbacioglu, L. Bullinger, S. Frohling, H. Dohner, and for the AML Study Group (AMLSG) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations Blood, December 1, 2005; 106(12): 3740 - 3746. [Abstract] [Full Text] [PDF] R. G. W. Verhaak, C. S. Goudswaard, W. van Putten, M. A. Bijl, M. A. Sanders, W. Hugens, A. G. Uitterlinden, C. A. J. Erpelinck, R. Delwel, B. Lowenberg, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance Blood, December 1, 2005; 106(12): 3747 - 3754. [Abstract] [Full Text] [PDF] N. Boissel, A. Renneville, V. Biggio, N. Philippe, X. Thomas, J.-M. Cayuela, C. Terre, I. Tigaud, S. Castaigne, E. Raffoux, et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype Blood, November 15, 2005; 106(10): 3618 - 3620. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020